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Peptides deduced from the central conserved region (residues 158 to 189) of protein G of human respiratory
syncytial virus (HRSV) subtypes A and B were used as antigens in subtype-specific enzyme-linked immunosor-
bent assays (G-peptide ELISAs). These G-peptide ELISAs were compared with seven other serological assays
to detect HRSV infection: ELISAs based on complete protein G, on fusion protein F, and on nucleoprotein N;
a complement fixation assay; a virus neutralization test; and ELISAs for the detection of immunoglobulin A
(IgA) or IgM antibodies specific for HRSV. In paired serum samples from patients with HRSV infection, more
infections were diagnosed by the G-peptide ELISA (67%) than by all other serological tests combined (48%).
Furthermore, for 16 of 18 patients (89%), the G-peptide ELISAs were able to differentiate between antibodies
against HRSV subtypes A and B. This study shows that peptides corresponding to the central conserved region
of the attachment protein G of HRSV can successfully be used as antigens in immunoassays. The G-peptide
ELISA appeared to be more sensitive than conventional tests for the detection of HRSV antibody titer rises.
Human respiratory syncytial virus (HRSV) is the most im-
portant causative agent of bronchiolitis and pneumonia in
young children. The virus is classified within the Pneumovirus
genus of the Paramyxoviridae. Efficacious vaccines against re-
spiratory syncytial virus (RSV) are not available. Because dif-
ferent antigenic subtypes are described for HRSV (6), it is
important for epidemiological studies and vaccine develop-
ments to monitor the prevailing subtypes in a population.
However, the available immunoassays (11) are based on whole
virus or complete proteins that do not discriminate between
subtypes of HRSV or between different RSV types.
The highly variable attachment protein G has limited ho-
mology between HRSV subtypes (53% amino acid homology)
(6). However, within the subtypes the amino acid homology is
much larger: .80% within HRSV subtype A (HRSV-A)
strains (3) and .90% within HRSV-B strains (10). Therefore,
protein G is a good candidate antigen for a discriminatory
assay. We proposed that the ectodomain of protein G contains
a central, conserved, relatively hydrophobic region bounded by
two hydrophilic, polymeric mucin-like regions (8). The central
conserved region of HRSV, bovine RSV, and ovine RSV is a
major antigenic site, and peptides corresponding to this region
can be used as antigens in immunoassays (1, 7–9).
In a previous study, it was shown that conventional serology
does not provide an adequate diagnostic tool for RSV infec-
tion in children younger than 6 months of age (2). In this study,
the data obtained by these conventional serological tests were
compared with those obtained by enzyme-linked immunosor-
bent assays (ELISAs) based on peptides corresponding to the
central conserved region of HRSV-A and HRSV-B. Further-
more, we demonstrated the applicability of the peptide-based
ELISA for subtype-specific diagnosis.
MATERIALS AND METHODS
Peptide synthesis. Peptides corresponding to the central conserved regions of
protein G (residues 158 to 189) of HRSV-A (12) and HRSV-B (6) were synthe-
sized (Fig. 1). Peptide synthesis has been described previously (7).
Serum samples and specimens. Paired serum specimens from 33 different
children (age, 0 to 6 months) with respiratory tract disease and suspected of
having RSV infection were taken in the acute phase and 3 to 4 weeks later.
Twenty-seven of these patients were confirmed to have an RSV infection by
direct immunofluorescence of cells from nasopharyngeal washings, virus isola-
tion on HEp-2 cells, and reverse transcription PCR (2). The RSV subtype was
identified by using RSV subtype-specific monoclonal antibodies (MAbs; MAb
92-11C for HRSV-A and MAb 109 for HRSV-B; Chemicon) in an immunoflu-
orescence assay with infected HEp-2 cells (2). Paired serum specimens from the
27 patients confirmed to be RSV positive were used to distinguish between
antibody reactivity against the HRSV-A G peptide or the HRSV-B G peptide.
Paired serum specimens from 14 mothers of the 14 HRSV-A-infected children
described above were taken at the same time that specimens were taken from
their children. These sera were tested in the HRSV-A G-peptide ELISA to
measure maternal antibody titers.
As a negative control, paired serum samples from six additional patients with
acute infections caused by influenza virus type A, Chlamydia psittaci, and Myco-
plasma pneumoniae, but not HRSV, were tested in the G-peptide ELISAs.
Two serum samples (samples 2369 and 2219) from two individuals (ages 2 and
3 years, respectively) positive for HRSV-specific antibodies collected during the
1993 to 1994 RSV epidemic were a kind gift of J. A. Melero, National Centre for
Microbiology (Madrid, Spain). These two serum specimens were tested by Pep-
scan analysis.
Pepscan analysis. Peptides were synthesized on functionalized polyethylene
rods and were tested for their reactivity with polyclonal antisera in an ELISA by
established procedures (4). Forty-seven overlapping dodecapeptides of the
ectodomain of the G protein of HRSV-A (12) between amino acids 153 and 211
were synthesized. This set of peptides includes all peptides corresponding to the
central conserved region.
Neutralization test. Twofold dilutions (starting at 1:10) of test sera were
incubated with 100 50% tissue culture infective doses of HRSV-A2 for 1 h at
37°C in 96-well tissue culture microtiter plates. HEp-2 cells were added to all
wells, and the plates were incubated for 3 days at 37°C in 5% CO2. The expres-
sion of viral antigen on the HEp-2 cells was detected by ELISA with an F-
protein-specific MAb (MAb 92-11C; Chemicon) and antimouse horseradish per-
oxidase (HRPO; Dako, Glostrup, Denmark). Both incubations were for 1 h at
37°C. Tetramethylbenzidine-H2O2 was used as the substrate. The reaction was
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stopped after 10 min with 0.2 M H2SO4. Absorption was read at 450 nm. The
percent virus neutralization was calculated by the following formula: (experimental
OD 2 cell control OD)/(virus control OD 2 cell control OD) 3 100, where OD
is optical density. The titer of the serum was defined as the dilution which gave
50% virus neutralization. Threefold titer rises were considered indicative of RSV
infection.
Competition ELISAs. Competition ELISAs for RSV fusion protein F, attach-
ment protein G, and nucleoprotein N were performed as described previously
(5). Partially purified RSV-A2 was coated (2 mg/well) onto 96-well ELISA plates
(Costar) overnight at 4°C. Dilutions of 100 ml of test sera (diluted 1:10 and 1:100)
were incubated in the wells for 2 h at room temperature. A highly positive serum
sample was used as the positive control (100% inhibition), and ELISA buffer
(phosphate-buffered saline, 3% extra NaCl, 0.1% bovine serum albumin, 0.1%
milk powder, 5% normal rabbit serum, 1% fetal calf serum) was used as a
negative control (0% inhibition). Subsequently, 50 ml of the serum dilution was
discarded and 50 ml of anti-F (133/1H; Chemicon MAb 858-1), anti-G (131/2G;
Chemicon MAb 858-2), or anti-N (23A3; Biosoft MAb 213-88) was added and
the mixture was incubated for 1 h at 37°C. Next, the wells were incubated with
HRPO-conjugated rabbit anti-mouse (Dako) for 1 h at 37°C. All dilutions were
made in ELISA buffer. Tetramethylbenzidine-H2O2 was used as the substrate.
The reaction was stopped after 10 min with 0.2 M H2SO4. Absorption was read
at 450 nm. Percent inhibition was calculated by the following formula: (experi-
mental OD 2 OD for 100% inhibition)/OD for 0% inhibition 2 OD for 100%
inhibition) 3 100. Threefold rises in the percentage of inhibition were consid-
ered indicative of RSV infection.
IgA and IgM capture ELISA. Anti-human immunoglobulin A (IgA) or IgM
was coated onto the wells of 96-well ELISA plates (Costar) overnight at 4°C. Test
sera (1:100), partially purified RSV, 50 ml of rabbit polyclonal anti-RSV serum
(Dako), and HRPO-conjugated goat anti-rabbit (Dako) were each subsequently
incubated for 1 h at 37°C. Tetramethylbenzidine-H2O2 was used as the substrate.
The reaction was stopped after 10 min with 0.2 M H2SO4. Absorption was read
at 450 nm. The cutoff value for positivity was more than two times the OD of a
negative sample. A positive reaction was confirmed by immunofluorescence test.
Indirect G-peptide ELISA procedure. The G-peptide ELISA was performed as
described previously (7), but with a modification in the coating procedure. One
hundred fifty nanograms of crude oxidized peptide in 50 ml of carbonate buffer
(0.05 M; pH 9.6) was coated per well (high-binding-capacity flat-bottom micro-
plate; Greiner) at 37°C overnight until all water was evaporated. Twofold dilu-
tions of test sera (starting at 1:10) and anti-human HRPO (1:1,000; Dako) were
incubated for 1 h at 37°C in ELISA buffer (8.1 mM Na2HPO4, 2.79 mM KH2PO4,
0.5 M NaCl, 2.68 mM KCl, 1 mM disodium EDTA, 0.05% [vol/vol] Tween 80
[pH 7.2]) containing 4% horse serum. The substrate chromogen solution con-
sisted of 10 mM sodium phosphate buffer (pH 6.8), 0.1 mM EDTA, 0.1%
(wt/vol) 5-aminosalicylic acid, and freshly added 0.005% (vol/vol) H2O2. Incu-
bation with substrate solution was performed overnight at 4°C. Color develop-
ment was measured at 450 nm (Titertek Multiscan). Absorbance values higher
than two times the average background value of test serum in control wells
without peptide were considered positive. Fourfold titer rises or seroconversion
(,10 to $20) in paired serum specimens are designated defined titer rises and
were considered indicative of RSV infection.
RESULTS
The reactivity of a panel of paired serum specimens was
tested in the HRSV-A and HRSV-B peptide ELISAs de-
scribed in Materials and Methods (Table 1). To evaluate the
HRSV specificity of the ELISAs, the reactivities of paired
serum specimens which showed antibody titer rises against
other agents were tested in both peptide ELISAs (Table 2). No
titer rises were observed for the negative controls.
In Table 1, titer rises may be missed because of the high titer
of the acute-phase serum. Because a high titer in the acute-
phase serum may be due to maternal antibodies, the paired
serum specimens from some of the mothers were tested in the
HRSV-A peptide ELISA (Table 3). No significant association
was found for the maternal antibody titer and the correspond-
ing titer in the acute-phase serum from the child (P 5 0.13,
according to Fisher’s exact test for two-way tables).
DISCUSSION
Detection of RSV infection in young children by conven-
tional serological tests as described in a previous study (2) was
FIG. 1. Schematic representation of primary structure of HRSV-G. Shaded
box, transmembrane region (TM). The primary structure of the synthesized pep-
tides corresponding to the central conserved region of the ectodomain is shown.
TABLE 1. Antibody titers in paired serum specimens from patients
with a respiratory infection determined by both G-peptide ELISAs
Patient no.
Titer by the following G-peptide ELISAa:
RSV type Peptide A Peptide B
2 A <10, 40 ,10, ,10
6 A 10, 80 ,10, ,10
9 A 20, 160 ,10, ,10
11 A 80, 40 ,10, ,10
17 A 10, 160 ,20, ,10
18 A 10, 10 ,10, ,10
19 A 10, 20 ,10, ,10
26 A <10, 40 ,10, ,10
27 A 10, 10 ,10, ,10
28 A <10, 40 ,10, ,10
30 A <10, 20 ,10, ,10
36 A <10, 640 ,10, ,10
37 A <10, 320 ,10, ,10
41 A 40, 80 ,10, ,10
7 B <10, 20 10, ,10
8 B 10, ,10 <10, 20
10 B 40, ,10 <10, 40
13 B 20, ,10 <10, 20
15 B ,10, 10 ,10, ,10
21 B 10, ,10 <10, 40
23 B 10, 10 <10, 80
24 B 10, 20 ,10, 10
25 B 10, ,10 ,10, ,10
35 B 10, ,10 <10, 40
38 B 10, 40 ,10, 10
39 B 10, 10 ,10, ,10
40 B ,10, ,10 <10, 20
1 ,10, ,10 ,10, ,10
4 <10, 40 ,10, ,10
5 ,10, ,10 ,10, ,10
12 ,10, ,10 ,10, ,10
14 ,10, ,10 ,10, ,10
29 ,10, ,10 ,10, ,10
a The pairs of values in each column are for the paired sera from each patient.
Titers in boldface represent defined titer rises.
TABLE 2. Antibody titers in paired serum specimens from patients
with a non-RSV infection determined by both G-peptide ELISAsa
Patient Non-HRSVinfection
Non-HRSV
titer rise
Titer by the following
G-peptide ELISA:
Peptide A Peptide B
WA Influenza virus type A 7, 32 320, 160 80, 80
B C. psittaci ,16, .64 80, 80 ,10, ,10
G Influenza virus type A 7, .96 40, 20 10, ,10
WB Influenza virus type A 12, 80 80, 80 10, 10
H M. pneumoniae ,16, 32 20, 10 10, ,10
V M. pneumoniae ,16, 64 640, 320 20, 20
a The pairs of values in the last three columns are for the paired sera from each
patient.
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compared with detection of RSV infection with the aid of
novel G-peptide ELISAs (Table 4). In summary, 18 of 27, 6 of
27, 0 of 27, 0 of 27, 6 of 27, 5 of 27, 0 of 27, and 0 of 27
specimens scored positive in the G-peptide ELISA, protein-G
ELISA, protein-F ELISA, protein-N ELISA, neutralization
test, IgA ELISA, IgM ELISA, and complement fixation test,
respectively (Table 4). The G-peptide ELISAs performed even
better (18 of 27 specimens) than the combination of all other
serological tests (12 of 27 specimens) (Table 4). Statistical
analyses of the sensitivity of different assays are presented in
Table 5. In 6 of the 33 patients, no virus or antigen could be
detected (see Materials and Methods) (2). In paired serum
specimens from these six patients not confirmed to be infected
with RSV, one RSV-specific antibody titer rise was detected in
the neutralization test (Table 4). In another patient not con-
firmed to be infected with RSV, a titer rise was observed in the
HRSV-A G-peptide ELISA. The latter two findings may sug-
gest that these sera reacted aspecifically. However, it may also
be possible that the virus or antigen detection test was false
negative or that the virus was already cleared from the body
before the patients entered the hospital. No titer rises were
detected in paired serum specimens from patients infected
with other agents (Table 2).
The HRSV-A and HRSV-B G-peptide ELISAs are selective
TABLE 3. Antibody titers in paired serum specimens from
mothers of patients with a respiratory infection
by HRSV-A G-peptide ELISA
Mother
Titer by
G-peptide ELISA
for peptide Aa
2 ............................................................................................ 10, 20
6 ............................................................................................ 10, 80
9 ............................................................................................ 160, 160
11b ......................................................................................... 160, 40
17 .......................................................................................... 20, 20
18 .......................................................................................... 20, 20
19 .......................................................................................... 40, 40
26 .......................................................................................... 40, 40
27 .......................................................................................... 20, 80
28 .......................................................................................... 160, 160
30 .......................................................................................... —c, 20
36 .......................................................................................... 10, 10
37 .......................................................................................... 10, 10
41 .......................................................................................... 40, 40
a The pairs of values are for the paired sera from each mother.
b Numbers in boldface represent mothers of children with a high acute-phase
serum titer.
c —, serum was not available.
TABLE 4. Detection of HRSV infection by several serological tests
Patient
no.
RSV
type
Peptide-A
ELISA
Peptide-B
ELISA
Protein-G
ELISAa
Protein-F
ELISAa
Protein-N
ELISAa
Neutraliza-
tion testa
IgA
ELISAa
IgM
ELISAa
Complement
fixation testa
2 A 1b 2c 1 2 2 1 2 2 2
6 A 1 2 2 2 2 2 2 2 2
9 A 1 2 1 2 2 1 2 2 2
11 A 2 2 2 2 2 2 2 2 2
17 A 1 2 2 2 2 2 1 2 2
18 A 2 2 2 2 2 2 1 2 2
19 A 2 2 2 2 2 2 2 2 2
26 A 1 2 2 2 2 2 2 2 2
27 A 2 2 2 2 2 2 1 2 2
28 A 1 2 1 2 2 2 2 2 2
30 A 1 2 1 2 2 2 1 2 2
36 A 1 2 1 2 2 1 2 2 2
37 A 1 2 2 2 2 1 2 2 2
41 A 2 2 2 2 2 2 2 2 2
7 B 1 2 2 2 2 2 2 2 2
8 B 2 1 2 2 2 2 2 2 2
10 B 2 1 1 2 2 2 2 2 2
13 B 2 1 2 2 2 2 2 2 2
15 B 2 2 2 2 2 2 2 2 2
21 B 2 1 2 2 2 1 1 2 2
23 B 2 1 2 2 2 2 2 2 2
24 B 2 2 2 2 2 1 2 2 2
25 B 2 2 2 2 2 2 2 2 2
35 B 2 1 2 2 2 2 2 2 2
38 B 1 2 2 2 2 2 2 2 2
39 B 2 2 2 2 2 2 2 2 2
40 B 2 1 2 2 2 2 2 2 2
1d 2 2 2 2 2 1 2 2 2
4d 1 2 2 2 2 2 2 2 2
5d 2 2 2 2 2 2 2 2 2
12d 2 2 2 2 2 2 2 2 2
14d 2 2 2 2 2 2 2 2 2
29d 2 2 2 2 2 2 2 2 2
a Data obtained from Brandenburg et al. (2).
b 1, defined antibody titer rise indicative of HRSV infection.
c 2, no defined antibody titer rise.
d Paired sera from patients in which no virus or antigen could be detected.
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for the subtype-specific detection of HRSV infection. Patients
infected with HRSV-A were only diagnosed positive by the
HRSV-A G-peptide ELISA. Patients infected with HRSV-B
were diagnosed positive seven times by the HRSV-B G-pep-
tide ELISA and twice by the HRSV-A G-peptide ELISA. The
reactivities of two paired serum specimens from supposedly
HRSV-B-infected children in the HRSV-A peptide ELISA is
puzzling. Several explanations can be conceived for this obser-
vation. First, the MAb-based subtype was wrong. This expla-
nation seems unlikely because the MAb-based subtype was
confirmed by subtype-specific PCR. Second, the child was in-
fected with both virus types, and an antibody response was
developed only against subtype A. Third, the cross-reactive
sera are directed against an epitope conserved in HRSV sub-
types A and B, and this epitope is better exposed in the
HRSV-A peptide. We do have some examples of sera that bind
to a conserved epitope in the N-terminal part of the HRSV-A
peptide (Fig. 2). Pepscan analysis showed two examples of
human sera that bound to five successive overlapping peptides
which shared the amino acid sequence DFHFEVFN (amino
acids 162 to 169). This sequence is conserved in HRSV-B
except for the mutation of F to Y at position 163 (Fig. 1). It is
possible that this relatively conserved epitope is responsible for
cross-reactivity in the peptide ELISA. Therefore, a smaller
peptide which only contains the more variable C-terminal part
of the central conserved region would seem more useful for
subtype-specific diagnosis. However, a 16-residue peptide
ELISA based on the shorter C-terminal peptide (residues 174
to 189) without the conserved part was significantly less sensi-
tive than the 32-residue peptide used in the assays (7). Perhaps
investigators will be able to find new immunodominant pep-
tides which can be combined with the 16-residue peptide to
develop an ELISA that is 100% subtype specific. However,
such peptides, derived from the highly variable mucin-like re-
gions, are probably strain specific and not completely subtype
specific.
In the sera of nine patients we did not detect a defined titer
rise in the HRSV-A or the HRSV-B peptide ELISA. In the
case of patients 11 and 41, this may be due to the high titer in
the first serum sample (Table 1). Perhaps the first sampling
date was too late for these two patients. We presumed that the
high titer of the acute-phase serum was probably not caused by
maternal antibodies since no evident association between the
antibody titer in the mother’s serum and the titer in the acute-
phase serum from the child was observed. The inability to
diagnose an RSV infection in the seven other patients may be
explained by a low or no antibody response in these children.
The patients were young or prematurely born children and
therefore may not have been fully immunocompetent. Two of
the five serum samples that did not react in the peptide ELISA
gave a positive response in the IgA ELISA only. Therefore, the
sensitivity of the peptide ELISA may be increased when the
reactivities of IgA antibodies are also tested.
The complete G-protein ELISA uses HRSV-A protein G as
the antigen. Fewer infections were detected by the ELISA
based on the complete HRSV-A protein G than by the ELISA
based on the HRSV-A G peptide. The higher sensitivity of the
HRSV-A G-peptide ELISA compared with that of the com-
plete protein-G ELISA may be explained partly by the differ-
ent format of the assays and the definition of a defined titer
rise. Important advantages of a peptide-based ELISA are the
low cost, the ease of production and the unvarying quality of
the peptide, and the coated microtiter plates. Furthermore, the
peptide-based RSV ELISA described in this study performs
better than conventional serological assays with sera from
these young children. Compared with other immunoassays, the
peptide-based ELISA is a sensitive immunoassay for the de-
tection of RSV infections. Despite considerable amino acid
sequence homology between the central conserved regions of
HRSV-A and HRSV-B proteins G, the peptide ELISA is spe-
cific for RSV subtype A and selective for subtype B-specific
antibody detection.
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